Site operations

Central IRB vs local IRB: what sites need to know

By TrialNotice · Updated
Five professionals discussing documents around an oval boardroom table with a city skyline behind them
Short answerA central or single IRB reviews a study once for all sites, instead of each site's local IRB reviewing it separately. Federally funded multisite research has required a single IRB under the revised Common Rule since January 2020. FDA proposed the same for FDA regulated multisite trials in September 2022, and HHS's 2026 regulatory agenda lists the final rule for December 2026, with a proposed effective date one year after publication.

What is the difference?

  • Local IRB: each institution's own board reviews the study for its site.
  • Central or single IRB: one board reviews the study for all participating sites. FDA has long permitted this; the reviewing IRB handles initial and continuing review, while the investigator and site stay responsible for conduct (FDA).

What is required today?

  • Federally funded research: the revised Common Rule's single IRB mandate for cooperative research has been in effect since January 2020 (Versiti).
  • FDA regulated research: current rules at 21 CFR 56.114 allow, but do not mandate, a single IRB (Versiti).

What is changing?

FDA proposed in September 2022 to require US institutions in FDA regulated multisite research to rely on a single IRB for the US portion, with some exceptions (Reginfo.gov). The 2026 HHS regulatory agenda lists the final rule for December 2026; it would also add a recordkeeping requirement when an institution relies on an IRB it does not operate (Advarra). FDA proposed an effective date one year after the final rule is published (PRIM&R). Agenda dates can slip, so watch for publication.

What does it mean for a community site?

Most independent sites already use central IRBs for industry trials, so the change mainly affects institutions with their own boards. The practical effect is faster, more uniform startup. Sponsors already favor familiar, fast sites; repeat sites finish startup 9.9 weeks faster (Tufts CSDD).

Where does that leave the race to enroll?

If IRB review stops being a differentiator, enrollment speed after activation becomes an even bigger one. Sites that brief referring physicians during startup are the ones that turn faster approvals into faster first patients. See why startup takes so long.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. FDA, "Cooperative Research" Information Sheet
  2. Versiti Clinical Trials, "FDA's Proposed Rule for IRBs on Cooperative Research"
  3. Reginfo.gov, HHS and FDA unified agenda entry: Institutional Review Boards; Cooperative Research
  4. Advarra, "2026 DHHS Unified Agenda: Four Areas HRPP and IRB Leaders Should Watch"
  5. PRIM&R, "FDA proposes new rule on Cooperative Research to harmonize with Common Rule"
  6. Tufts CSDD, first comprehensive clinical site initiation benchmark (2018), via GlobeNewswire

Keep reading

Clinical research coordinator in a rust sweater smiling on a phone call by an office window with autumn trees outside
Site operations

Why research coordinators leave, and how sites keep them

Site turnover runs 35% to 61% a year, and 85% of departing staff go to sponsors and CROs. Here is why coordinators leave, what turnover costs a site, and what keeps them.

 Principal investigator with a gray beard walking down a research clinic corridor with a coordinator in teal scrubs
Site operations

Sponsor training burden: where coordinator hours really go

Sites average 17.5 hours per study per month on training, and 65% of mandatory training is considered redundant. Here is the data, the industry efforts to cut it, and what sites can do now.

 Clinical research coordinator welcoming the first study patient at a research clinic entrance
Site operations

Why study startup takes so long, and where sites lose weeks

Study startup averages 31.4 weeks from site identification, and the contract and budget stages take the largest share. Here is where the time goes and which delays a site controls.